Ferdinand Seith1, Andrea Forschner2, Holger Schmidt3, Christina Pfannenberg3, Brigitte Gückel3, Konstantin Nikolaou3,4, Christian la Fougère4,5, Claus Garbe2, Nina Schwenzer3. 1. Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany. ferdinand.seith@med.uni-tuebingen.de. 2. Department of Dermatology, Eberhard Karls University, Liebermeisterstrasse 25, 72076, Tuebingen, Germany. 3. Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany. 4. German Cancer Consortium (DKTK), Heidelberg, Germany. 5. Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, Eberhard Karls University, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Abstract
PURPOSE: The aim of the study was to evaluate if 18F-FDG-PET has the potential to detect complete responders to PD1-therapy in patients with unresectable metastasized melanoma two weeks after therapy initiation. METHODS: Between September 2014 and May 2016, ten patients (four females; 65 ± 12 y) received a whole-body 18F-FDG-PET/MRI examination at three time points: Before therapy start (t0, base-line), two weeks (t1, study examination) and three months after treatment initiation (t2, reference standard). Therapy response was assessed with PET response criteria in solid tumors (PERCIST). Time to progression and overall survival (OS) were obtained for all patients. RESULTS: Three patients with partial metabolic response in PET at t1 turned out to have complete response at t2. No tumor relapse was observed in those patients so far (observation period: 265, 511 and 728 days, respectively). At t2, progressive metabolic disease (PMD) was seen in six patients from whom four showed PMD and two showed stable metabolic disease (SMD) at t1. OS in patients with PMD at t2 varied between 148 and 814 days. SMD at both t1 and t2 was seen in one patient, tumor progress was observed after 308 days. CONCLUSION: Our study indicates that whole-body 18F-FDG-PET might be able to reliably identify complete responders to PD1-therapy as early as two weeks after therapy initiation in stage IV melanoma patients. This might help to shorten therapy regimes and avoid unnecessary side effects in the future.
PURPOSE: The aim of the study was to evaluate if 18F-FDG-PET has the potential to detect complete responders to PD1-therapy in patients with unresectable metastasized melanoma two weeks after therapy initiation. METHODS: Between September 2014 and May 2016, ten patients (four females; 65 ± 12 y) received a whole-body 18F-FDG-PET/MRI examination at three time points: Before therapy start (t0, base-line), two weeks (t1, study examination) and three months after treatment initiation (t2, reference standard). Therapy response was assessed with PET response criteria in solid tumors (PERCIST). Time to progression and overall survival (OS) were obtained for all patients. RESULTS: Three patients with partial metabolic response in PET at t1 turned out to have complete response at t2. No tumor relapse was observed in those patients so far (observation period: 265, 511 and 728 days, respectively). At t2, progressive metabolic disease (PMD) was seen in six patients from whom four showed PMD and two showed stable metabolic disease (SMD) at t1. OS in patients with PMD at t2 varied between 148 and 814 days. SMD at both t1 and t2 was seen in one patient, tumor progress was observed after 308 days. CONCLUSION: Our study indicates that whole-body 18F-FDG-PET might be able to reliably identify complete responders to PD1-therapy as early as two weeks after therapy initiation in stage IV melanomapatients. This might help to shorten therapy regimes and avoid unnecessary side effects in the future.
Entities:
Keywords:
18F-FDG-PET; Early response assessment; Immunotherapy; Melanoma
Authors: Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: Steve Y Cho; Evan J Lipson; Hyung-Jun Im; Steven P Rowe; Esther Mena Gonzalez; Amanda Blackford; Alin Chirindel; Drew M Pardoll; Suzanne L Topalian; Richard L Wahl Journal: J Nucl Med Date: 2017-03-30 Impact factor: 10.057
Authors: Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245
Authors: Urban Simoncic; Sara Leibfarth; Stefan Welz; Nina Schwenzer; Holger Schmidt; Gerald Reischl; Christina Pfannenberg; Christian la Fougère; Konstantin Nikolaou; Daniel Zips; Daniela Thorwarth Journal: Med Phys Date: 2017-04-20 Impact factor: 4.071
Authors: Andrea Forschner; Tobias Sinnberg; Gabi Mroz; Christopher Schroeder; Christian Philipp Reinert; Sergios Gatidis; Michael Bitzer; Thomas Eigentler; Claus Garbe; Heike Niessner; Martin Röcken; Cristiana Roggia; Sorin Armeanu-Ebinger; Olaf Riess; Sven Mattern; Dominik Nann; Irina Bonzheim Journal: Front Oncol Date: 2021-03-01 Impact factor: 6.244